• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Dow Jumps 250 Points; US Weekly Jobless Claims Edge Higher

    12/21/23 9:48:30 AM ET
    $CLNN
    $DMK
    $HOOK
    $NOGN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CLNN alert in real time by email

    U.S. stocks traded higher this morning, with the Dow Jones gaining around 250 points on Thursday.

    Following the market opening Thursday, the Dow traded up 0.72% to 37,348.90 while the NASDAQ rose 0.96% to 14,919.80. The S&P 500 also rose, gaining, 0.78% to 4,734.96.

    Check This Out: Amazon.com To Rally Over 38%? Here Are 10 Top Analyst Forecasts For Thursday

     

    Leading and Lagging Sectors

     

    Information technology shares jumped by 1.1% on Thursday.

    In trading on Thursday, energy shares rose by just 0.3%.

     

    Top Headline

     

    U.S. initial jobless claims rose by 2,000 to 205,000 in the week ending Dec. 16, compared to market expectations of 215,000.

     

    Equities Trading UP

     

    Infrared Cameras Holdings, Inc. (NASDAQ:MSAI) shares shot up 112% to $5.57 after falling over 61% on Wednesday.

    Shares of HOOKIPA Pharma Inc. (NASDAQ:HOOK) got a boost, surging 54% to $0.8689 after the company announced a $21.25 million equity investment from Gilead Sciences.

    DMK Pharmaceuticals Corporation (NASDAQ:DMK) shares were also up, gaining 47% to $0.8697. DMK Pharmaceuticals regained full rights to commercialize ZIMHI after the termination of an exclusive commercialization and distribution with US WorldMeds, LLC.

     

    Equities Trading DOWN

     

    Polished.com Inc. (NYSE:POL) shares dropped 42% to $4.36 after jumping 618% on Wednesday.

    Shares of Clene Inc. (NASDAQ:CLNN) were down 38% to $0.32. Clene reported new data from 12-month long-term open label extension of CNM-Au8 treatment arm in HEALEY ALS platform trial.

    Nogin, Inc. (NASDAQ:NOGN) was down, falling 32% to $0.0764 after dipping over 30% on Wednesday.

    Also Check This Out: How To Earn $500 A Month From Broadcom Stock Following Recent Rally

     

    Commodities

     

    In commodity news, oil traded down 1.6% to $73.04 while gold traded up 0.2% at $2,051.80.

    Silver traded down 0.4% to $24.545 on Thursday while copper rose 0.4% to $3.9210.

     

    Euro zone

     

    European shares were mostly lower today. The eurozone’s STOXX 600 fell 0.2%, London’s FTSE 100 fell 0.4% while Spain’s IBEX 35 Index rose 0.01% The German DAX fell 0.2% French CAC 40 fell 0.2%, while Italy’s FTSE MIB Index fell 0.4%.

    The manufacturing climate indicator in France climbed to 100 in December versus 99 in the prior month. Industrial producer prices in Italy fell 12.6% year-over-year in November following a 9.5% decline a month ago.

     

    Asia Pacific Markets

     

    Asian markets closed mostly higher on Thursday, with Japan’s Nikkei 225 falling 1.59%, Hong Kong’s Hang Seng Index gaining 0.04% and China’s Shanghai Composite Index gaining 0.57%. India’s S&P BSE Sensex, meanwhile, rose 0.51%.

    The annual inflation rate in Hong Kong fell to 2.6% in November compared to October’s one-year high level of 2.7%. Hong Kong’s current account surplus shrank to HKD 103.6 billion in the third quarter compared to HKD 117.3 billion in the year-ago period.

     

    Economics

     

    The Philadelphia Fed Manufacturing Index in the U.S. fell to -10.5 in December from -5.9 in the previous month.

    Corporate profits in the U.S. increased by 3.7% from the prior period to $2.698 trillion in the third quarter.

    U.S. initial jobless claims rose by 2,000 to 205,000 in the week ending Dec. 16, compared to market expectations of 215,000.

    The U.S. economy grew an annualized 4.9% in the third quarter, down from 5.2% in the second estimate, but matching the 4.9% reading in the advance estimate.

    Now Read This: Top 5 Industrials Stocks That Are Ticking Portfolio Bombs

    Get the next $CLNN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CLNN
    $DMK
    $HOOK
    $NOGN

    CompanyDatePrice TargetRatingAnalyst
    HOOKIPA Pharma Inc.
    $HOOK
    12/20/2024$48.00 → $2.00Outperform → Sector Perform
    RBC Capital Mkts
    HOOKIPA Pharma Inc.
    $HOOK
    11/15/2024$50.00 → $48.00Outperform
    RBC Capital Mkts
    HOOKIPA Pharma Inc.
    $HOOK
    12/2/2022Neutral → Underperform
    BofA Securities
    Clene Inc.
    $CLNN
    10/4/2022Outperform → Perform
    Oppenheimer
    Clene Inc.
    $CLNN
    7/18/2022$16.00Buy
    H.C. Wainwright
    Clene Inc.
    $CLNN
    5/2/2022$10.00Buy
    Canaccord Genuity
    HOOKIPA Pharma Inc.
    $HOOK
    2/17/2022$15.00 → $8.00Buy
    HC Wainwright & Co.
    HOOKIPA Pharma Inc.
    $HOOK
    2/16/2022$3.00 → $4.00Outperform
    SVB Leerink
    More analyst ratings

    $CLNN
    $DMK
    $HOOK
    $NOGN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Ugwumba Chidozie sold $22,792 worth of shares (5,559 units at $4.10) (SEC Form 4)

    4 - Clene Inc. (0001822791) (Issuer)

    2/5/26 10:18:03 AM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Ugwumba Chidozie sold $104,862 worth of shares (24,770 units at $4.23) (SEC Form 4)

    4 - Clene Inc. (0001822791) (Issuer)

    2/2/26 5:10:00 PM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Ugwumba Chidozie sold $96,045 worth of shares (19,274 units at $4.98) (SEC Form 4)

    4 - Clene Inc. (0001822791) (Issuer)

    1/28/26 5:01:41 PM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CLNN
    $DMK
    $HOOK
    $NOGN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Matlin David J bought $216,664 worth of shares (33,333 units at $6.50), increasing direct ownership by 7% to 477,824 units (SEC Form 4)

    4 - Clene Inc. (0001822791) (Issuer)

    1/13/26 2:48:54 PM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Matlin David J bought $438,458 worth of shares (92,307 units at $4.75), increasing direct ownership by 26% to 444,491 units (SEC Form 4)

    4 - Clene Inc. (0001822791) (Issuer)

    10/2/24 12:58:21 PM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Science Officer Mortenson Mark bought $97,432 worth of shares (20,512 units at $4.75), increasing direct ownership by 243% to 28,949 units (SEC Form 4)

    4 - Clene Inc. (0001822791) (Issuer)

    10/1/24 4:17:45 PM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CLNN
    $DMK
    $HOOK
    $NOGN
    SEC Filings

    View All

    Clene Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

    8-K - Clene Inc. (0001822791) (Filer)

    1/13/26 4:36:05 PM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Clene Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Clene Inc. (0001822791) (Filer)

    1/12/26 8:30:31 AM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by Clene Inc.

    424B5 - Clene Inc. (0001822791) (Filer)

    1/9/26 4:25:22 PM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CLNN
    $DMK
    $HOOK
    $NOGN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    HOOKIPA Pharma downgraded by RBC Capital Mkts with a new price target

    RBC Capital Mkts downgraded HOOKIPA Pharma from Outperform to Sector Perform and set a new price target of $2.00 from $48.00 previously

    12/20/24 7:37:05 AM ET
    $HOOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    RBC Capital Mkts reiterated coverage on HOOKIPA Pharma with a new price target

    RBC Capital Mkts reiterated coverage of HOOKIPA Pharma with a rating of Outperform and set a new price target of $48.00 from $50.00 previously

    11/15/24 11:07:50 AM ET
    $HOOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HOOKIPA Pharma downgraded by BofA Securities

    BofA Securities downgraded HOOKIPA Pharma from Neutral to Underperform

    12/2/22 12:03:07 PM ET
    $HOOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CLNN
    $DMK
    $HOOK
    $NOGN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    HOOKIPA Pharma Announces Sale of Oncology Assets to NeoTrail Therapeutics

    NEW YORK and VIENNA, Austria, Feb. 03, 2026 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (OTCID: HOOK, "HOOKIPA", the "Company") today announced the sale of its immuno-oncology related assets, consisting primarily of the HB-200 (eseba-vec) and HB-700 development programs, to NeoTrail Therapeutics, Inc. ("NeoTrail"). The purchase price remains undisclosed. "We are delighted that the clinical development of these promising therapeutics will continue at NeoTrail with an opportunity to deliver patient benefit in multiple major market indications," stated Mark Winderlich, Chief R&D Officer of HOOKIPA. The asset purchase agreement was signed on January 28, 2026, and the transaction is expected to c

    2/3/26 8:30:00 AM ET
    $HOOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Presenting on Emerging Growth Conference 89 Day 2 on January 22; Register to live stream

    MIAMI, Jan. 21, 2026 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of Day 2 of the 89th Emerging Growth Conference on January 21 & 22, 2026. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: [email protected] For updates, follow us on Twitter Day 1 - Presenting Today - January 21, 2026 8:45Virtual Lobby opens.Register for the Conference. If you alread

    1/21/26 7:00:00 AM ET
    $CLNN
    $DEVS
    $DGXX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Finance/Investors Services
    Finance

    Presenting on Emerging Growth Conference 89 Day 1 on January 21; Register to live stream

    MIAMI, Jan. 20, 2026 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 89th Emerging Growth Conference on January 21 & 22, 2026. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: [email protected] For updates, follow us on Twitter Day 1 - WednesdayJanuary 21, 2026 8:45Virtual Lobby opens.Register for the Conference. If you already registered, go ba

    1/20/26 7:00:00 AM ET
    $CLNN
    $DEVS
    $DGXX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Finance/Investors Services
    Finance

    $CLNN
    $DMK
    $HOOK
    $NOGN
    Leadership Updates

    Live Leadership Updates

    View All

    HOOKIPA Pharma Reports Third Quarter 2024 Financial Results and Provides Recent Business Updates

    Enrollment of 68 patients completed Phase 2 study for eseba-vec + pembrolizumab in HPV+ HNSCC four months ahead of schedule SITC 2024 late-breaking poster highlights Phase 2 eseba-vec data updates for increased number of patients reflecting ORR and durability in line with prior data First patients dosed in Phase 2 investigator led study with MSKCC in new clinical setting as adjuvant therapy for head and neck cancer Strength of HB-700 KRAS-inhibitor program highlighted by preclinical dataset presented at recent RAS Targeted Drug Development Summit NEW YORK and VIENNA, Austria, Nov. 14, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK, "HOOKIPA", the "Company")

    11/14/24 4:05:00 PM ET
    $HOOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HOOKIPA Pharma Announces Board of Directors Changes

    NEW YORK and VIENNA, Aug. 30, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK) ("HOOKIPA" or the "Company"), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced the appointment of Director Julie O'Neill as Non-Executive Chair of the Company's Board of Directors. She succeeds Jan van de Winkel, who has decided to step down from the Board effective August 30, 2024, due to increasing time commitments from his executive position as Chief Executive Officer of Genmab A/S. The Company also announced that Tim Reilly has chosen to step down from the Board, also effective August 30th, to be able to dedicate more time to his o

    8/30/24 8:00:00 AM ET
    $HOOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HOOKIPA Pharma Reports Second Quarter 2024 Financial Results and Recent Business Highlights

    New Leadership Appointments; Positive Clinical and Regulatory Reports for the Lead Product Candidate, HB-200 (eseba-vec); On track to initiate the Phase 2/3 "AVALON-1" study with eseba-vec in Q4 2024 ASCO 2024 Presentation:   Reported best-in-class Phase 2 data for first-line HPV16+ head and neck cancer patients treated with eseba-vec (formerly HB-200) in combination with pembrolizumab during oral presentation at the American Society of Clinical Oncology (ASCO) 2024 Annual MeetingRegulatory Progress:   Announced alignment with U.S. Food and Drug Administration (FDA) for the AVALON-1 Phase 2/3 pivotal trial design and protocol for eseba-vec, in combination with pembrolizumab for the first-li

    8/8/24 4:30:00 PM ET
    $HOOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CLNN
    $DMK
    $HOOK
    $NOGN
    Financials

    Live finance-specific insights

    View All

    Clene Announces Statistically Significant ALS Biomarker Results Supporting Accelerated Approval Pathway for CNM-Au8®

    FDA recommended biomarker analyses show statistically significant reductions in NfL and GFAP in participants treated with CNM-Au8Biomarker improvements are strongly associated with longer survival, reinforcing CNM-Au8's potential disease modifying activityCompany has requested a Type C meeting in the first quarter of 2026 to present the newly completed analyses supporting a planned NDA submission under the accelerated approval pathwayClene is hosting an investor webcast today at 8:30 am ET SALT LAKE CITY, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ:CLNN) (along with its subsidiaries, "Clene" or the "Company") and its wholly owned subsidiary Clene Nanomedicine, Inc., a late clinic

    12/3/25 8:00:00 AM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HOOKIPA Pharma Announces Updated Phase 2 Clinical Data at the American Society of Clinical Oncology 2024 Annual Meeting

    Encouraging clinical activity with observed deepening of responses in 35 evaluable first line head and neck patients treated with HB-200 plus pembrolizumabIn a subset of 17 evaluable patients with PD-L1 combined positive score (CPS) of 20 or higher, the Company's selected registrational pivotal trial population, data showed confirmed ORR of 53%, CR rate of 18%, and DCR of 82%Preliminary progression-free survival (PFS) was 16.3 months and preliminary overall survival (OS) rate was 88% at 9 months for the CPS 20 or higher subgroup, comparing favorably to current standard of careCompany will host a conference call at 4:15 p.m. ET today NEW YORK and VIENNA, June 04, 2024 (GLOBE NEWSWIRE) -- H

    6/4/24 1:00:44 PM ET
    $HOOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HOOKIPA Pharma Announces Pivotal Phase 2/3 Trial Design for HB-200 in Combination with Pembrolizumab

    Phase 2/3 pivotal trial design and protocol for HB-200 in combination with pembrolizumab for the first-line treatment of patients with HPV16+ recurrent or metastatic OPSCC aligned with FDA feedback HB-200 accepted for oral abstract presentation at ASCO 2024 Annual Meeting with data from approximately 40 patients treated with HB-200 in combination with pembrolizumab Two additional abstracts for HB-200 and HB-700 accepted for the ASCO 2024 Annual Meeting Company to host investor call at 8:00 a.m. ET on Thursday, April 25, 2024, to highlight path to potential registration; participant details below NEW YORK and VIENNA, Austria, April 25, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDA

    4/25/24 7:01:00 AM ET
    $HOOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CLNN
    $DMK
    $HOOK
    $NOGN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by HOOKIPA Pharma Inc.

    SC 13G/A - HOOKIPA Pharma Inc. (0001760542) (Subject)

    11/14/24 6:07:08 PM ET
    $HOOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Clene Inc.

    SC 13G/A - Clene Inc. (0001822791) (Subject)

    11/14/24 3:32:55 PM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Clene Inc.

    SC 13G - Clene Inc. (0001822791) (Subject)

    11/14/24 3:26:45 PM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care